Eli Lil­ly part­ner Ab­Cellera finds a CBO in the face of bam­lanivimab strug­gles; Fi­bro­Gen's next CSO walks in­to rox­adu­s­tat re­buff

→ Covid-19 vari­ants have marred the ef­fec­tive­ness of Eli Lil­ly and Ab­Cellera’s bam­lanivimab to such an ex­tent that the US gov­ern­ment stopped us­ing the mon­o­clon­al an­ti­body in March, fol­lowed by a sim­i­lar halt for the com­bo treat­ment with ete­se­vimab late last month. Ab­Cellera is nonethe­less press­ing on­ward with a new can­di­date for mild to mod­er­ate cas­es, LY-CoV1404, and this week Neil Berkley joined Carl Hansen’s squad as CBO. Berkley, a Glax­o­SmithK­line neu­ro­science vet­er­an, makes the leap from Halozyme, start­ing out at the San Diego biotech as head of on­col­o­gy glob­al part­ner­ing, cor­po­rate de­vel­op­ment in 2019 and earn­ing a pro­mo­tion to VP, head of busi­ness de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER